

114TH CONGRESS  
2D SESSION

# S. 2994

To amend the Federal Food, Drug, and Cosmetic Act to prevent the abuse of dextromethorphan, and for other purposes.

---

IN THE SENATE OF THE UNITED STATES

MAY 26, 2016

Mr. CASEY (for himself and Ms. MURKOWSKI) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

---

## A BILL

To amend the Federal Food, Drug, and Cosmetic Act to prevent the abuse of dextromethorphan, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “DXM Abuse Preven-  
5 tion Act of 2016”.

1 **SEC. 2. SALES OF OVER-THE-COUNTER DRUGS CONTAINING**  
 2 **DEXTROMETHORPHAN.**

3 (a) PROHIBITED ACT.—Section 301 of the Federal  
 4 Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amend-  
 5 ed by adding at the end the following:

6 “(eee) The failure of a retailer to implement a  
 7 verification system as required by section 506G (relating  
 8 to sales of over-the-counter drugs containing  
 9 dextromethorphan).”.

10 (b) VERIFICATION SYSTEM.—The Federal Food,  
 11 Drug, and Cosmetic Act is amended by inserting after sec-  
 12 tion 506F of such Act (21 U.S.C. 356f) the following:

13 **“SEC. 506G. SALES OF OVER-THE-COUNTER DRUGS CON-**  
 14 **TAINING DEXTROMETHORPHAN.**

15 “(a) VERIFICATION SYSTEM.—Any retailer selling or  
 16 offering for sale in interstate commerce dextromethorphan  
 17 shall implement a verification system to ensure compliance  
 18 with this section. Such a system may ensure such compli-  
 19 ance by means of—

20 “(1) an electronic point-of-sale system coded to  
 21 prompt for verification of the age of all purchasers  
 22 of drugs described in subsection (b) and deny sales  
 23 to those under the age of 18;

24 “(2) training manuals or materials instructing  
 25 employees to verify the age of all purchasers of such  
 26 drugs and deny sales to those under the age of 18;

1           “(3) signage in and around the sales counter  
2           outlining the age restriction on sales of such drugs;

3           “(4) designating one on-duty employee to ap-  
4           prove all sales of such drugs; or

5           “(5) any other verification measure deemed  
6           valid by the Secretary.

7           “(b) PROHIBITION.—Except as provided in sub-  
8           section (c), each retailer shall verify that no individual is  
9           under 18 years of age who purchases any drug that—

10           “(1) contains dextromethorphan; and

11           “(2) is not subject to section 503(b)(1).

12           “(c) EXCEPTIONS.—

13           “(1) INDIVIDUALS OVER 26.—Subsection (b)  
14           does not require verification of the age of any indi-  
15           vidual over the age of 26.

16           “(2) VALID PRESCRIPTION.—Subsection (b)  
17           does not apply to any sale made pursuant to a val-  
18           idly issued prescription.

19           “(3) VALID MILITARY IDENTIFICATION CARD.—  
20           Subsection (b) does not apply to any sale to an indi-  
21           vidual under 18 years of age if such individual sup-  
22           plies proof at the time of such sale that such indi-  
23           vidual is actively enrolled in the military and pre-  
24           sents a valid military identification card.

1 “(d) AFFIRMATIVE DEFENSE.—It shall be an affirm-  
2 ative defense to an alleged violation of subsection (b) that  
3 the individual selling a drug containing  
4 dextromethorphan—

5 “(1) examined the purchaser’s identification  
6 card; and

7 “(2) based on that examination, reasonably con-  
8 cluded that the identification was valid and indicated  
9 that the purchaser was not less than 18 years of  
10 age.

11 “(e) DEFINITION.—In this paragraph, the term  
12 ‘identification card’ means an identification card that—

13 “(1) includes a photograph and the date of  
14 birth of the individual; and

15 “(2) is issued by a State or the Federal Govern-  
16 ment or is considered acceptable for purposes of sec-  
17 tions 274a.2(b)(1)(v)(A) and 274a.2(b)(1)(v)(B)(1)  
18 of title 8, Code of Federal Regulations (including  
19 any successor regulations).”.

20 (e) CIVIL PENALTIES.—Section 303 of the Federal  
21 Food, Drug, and Cosmetic Act (21 U.S.C. 333) is amend-  
22 ed by adding at the end the following:

23 “(h) Notwithstanding subsection (a), the following  
24 provisions shall apply to violations of section 301(eee):

1           “(1) A person who violates section 301(eee)  
2 shall—

3           “(A) receive a violation notification from  
4 the Secretary for the first such violation; and

5           “(B) be subject to a civil penalty in an  
6 amount—

7           “(i) not more than \$1,000 for the sec-  
8 ond such violation by a person;

9           “(ii) not more than \$2,000 for the  
10 third such violation by a person; and

11           “(iii) not more than \$5,000 for the  
12 fourth such violation, or a subsequent such  
13 violation, by a person.

14           “(2) In determining the amount of a civil pen-  
15 alty under this subsection for a person who is a re-  
16 tailer, the Secretary shall consider whether the re-  
17 tailer has taken appropriate steps to prevent subse-  
18 quent violations, such as the establishment and ad-  
19 ministration of a documented employee training pro-  
20 gram to ensure all employees are familiar with and  
21 abiding by the provisions of section 506G, where  
22 such program includes—

23           “(A) educating employees regarding prod-  
24 ucts containing dextromethorphan;

1           “(B) instruction on the correct method of  
2           checking a purchaser’s identification card; and

3           “(C) notifying employees of the civil pen-  
4           alties under this subsection.

5           “(3) If a person who is a retailer transacts  
6           sales of products containing dextromethorphan at  
7           more than one physical location, for purposes of de-  
8           termining the number of violations by that person  
9           under this subsection, each individual physical loca-  
10          tion operated by that retailer shall be considered a  
11          separate person.

12          “(4) The Secretary shall notify persons found  
13          to have violated section 301(eee) as soon as prac-  
14          ticable after the Secretary discovers such violation.  
15          Such notification shall include the date and time  
16          when the violation was observed to occur.

17          “(5) Notwithstanding any other provision of  
18          this subsection or section 301(eee), an employee  
19          shall not be subject to penalties under this sub-  
20          section unless such employee knowingly and willfully  
21          participates in a conspiracy to violate section  
22          301(eee). For purposes of this paragraph, a con-  
23          spiracy shall consist of an agreement between 2 or  
24          more persons with the intent to violate section

1 301(eee) and the commission of at least one overt  
2 act in furtherance of the agreement.

3 “(6) In this subsection—

4 “(A) the term ‘employee’ means an indi-  
5 vidual who is employed by a retailer in a cler-  
6 ical or other non-managerial position; and

7 “(B) the term ‘retailer’ means a grocery  
8 store, general merchandise store, drug store,  
9 pharmacy, convenience store, or other entity or  
10 person whose activities as a distributor relating  
11 to products containing dextromethorphan are  
12 limited almost exclusively to sales for personal  
13 use, both in number of sales and volume of  
14 sales, including any sales made by the Internet  
15 or other means.”.

16 **SEC. 3. RESTRICTIONS ON DISTRIBUTION OF BULK**  
17 **DEXTROMETHORPHAN.**

18 The Federal Food, Drug, and Cosmetic Act (21  
19 U.S.C. 321 et seq.) is amended—

20 (1) in section 501, by adding at the end the fol-  
21 lowing:

22 “(k) If it is unfinished dextromethorphan and is pos-  
23 sessed, received, or distributed in violation of section  
24 506H.”;

1           (2) by inserting after section 506G, as added by  
2           section 2(b), the following:

3 **“SEC. 506H. RESTRICTIONS ON THE DISTRIBUTION OF**  
4 **BULK DEXTROMETHORPHAN.**

5           “(a) IN GENERAL.—No person shall—

6           “(1)     possess     or     receive     unfinished  
7           dextromethorphan, unless the person is registered  
8           under section 510 or otherwise registered, licensed,  
9           or approved pursuant to Federal or State law to en-  
10          gage in the practice of pharmacy, pharmaceutical  
11          production, or manufacture or distribution of drug  
12          ingredients; or

13          “(2) distribute unfinished dextromethorphan to  
14          any person other than a person registered under sec-  
15          tion 510 or otherwise registered, licensed, or ap-  
16          proved pursuant to Federal or State law to engage  
17          in the practice of pharmacy, pharmaceutical produc-  
18          tion, or manufacture or distribution of drug ingredi-  
19          ents.

20          “(b) EXCEPTION FOR COMMON CARRIERS.—This  
21          section does not apply to a common carrier that possesses,  
22          receives, or distributes unfinished dextromethorphan for  
23          purposes     of     distributing     such     unfinished  
24          dextromethorphan between persons described in sub-  
25          section (a) as registered, licensed, or approved.

1 “(c) DEFINITIONS.—In this section:

2 “(1) The term ‘common carrier’ means any per-  
3 son that holds itself out to the general public as a  
4 provider for hire of the transportation by water,  
5 land, or air of merchandise, whether or not the per-  
6 son actually operates the vessel, vehicle, or aircraft  
7 by which the transportation is provided, between a  
8 port or place and a port or place in the United  
9 States.

10 “(2) The term ‘unfinished dextromethorphan’  
11 means dextromethorphan that is not contained in a  
12 drug that is in finished dosage form.”; and

13 (3) by amending section 303, as amended by  
14 section 2(c), by adding at the end the following:

15 “(i) Notwithstanding subsection (a), a person who  
16 violates section 506H shall be subject to a civil penalty  
17 of not more than \$100,000.”.

○